News

According to results of a phase I trial, the addition of the CDK 4/6 inhibitor palbociclib can help patients with mantle cell lymphoma overcome resistance to the BTK inhibitor ibrutinib.

Pembrolizumab demonstrated durable activity in 3 clinical trials in previously treated patients with mucosal melanoma.

Based on data from 2 phase III trials, the EMA’s CHMP has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant for patients with newly diagnosed multiple myeloma.

Lead study author Jennifer A. Woyach, MD, discusses a phase II trial of MOR208, which includes cohorts of patients with relapsed/refractory CLL, treatment-naïve disease, Richter’s transformation, and those with CLL who have been treated with ibrutinib.

A prostate-specific antigen nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy seems to identify men prior to PSA failure who are at high-risk for death, and would thus require more aggressive treatment for their prostate cancer.

Tudor Borza, MD,  discusses the major findings of his study that found a sharp decline in the overall rate of men receiving treatment for prostate cancer and his stance on the importance of prostate cancer screening and treatment.

The University of Texas MD Anderson Cancer Center has united with the 68 other National Cancer Institute–designated cancer centers in issuing a joint statement that endorses the recently revised vaccination recommendations from the CDC.

Lenvatinib was shown to be noninferior to standard therapy with sorafenib in the frontline treatment of patients with unresectable hepatocellular carcinoma.

Evanthia Galanis, MD, discusses the issues that currently exist in clinical trial design in oncology and neuro-oncology, as well as how they can be addressed.

Saad Z. Usmani, MD, discusses the POLLUX update and PAVO findings presented at ASH, as well as the latest developments with daratumumab.

According to results from a randomized clinical trial,^&nbsp;adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with <em>BRAF</em>-mutant metastatic colorectal cancer.

Elizabeth Plimack, MD,&nbsp;discusses the 2-year updated data from the CheckMate-025 trial in RCC, as well as the remaining questions with nivolumab in this setting.

In the treatment of patients with renal cell carcinoma, there has been a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors.

In an update of the phase II CheckMate-142 trial,&nbsp;the promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained.

Alberto Montero, MD, discusses the significance of the PERTAIN study in estrogen-positive, HER2-positive patients.

Tian Zhang, MD,&nbsp;discusses the challenges associated with vaccine development in kidney cancer and the hope that vaccines can still be the answer to improving the response rates with anti&not;&ndash;PD-1/PD-L1 treatment in RCC.

Carolyn E. Banister, MD, highlights the major findings of her study that discovered a new subtype of cervical cancer and the significant therapeutic implications that will follow.&nbsp;

Two separate delays have been announced by Bristol-Myers Squibb and AstraZeneca in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non&ndash;small cell lung cancer.

BRAF inhibitor encorafenib combined with the MEK inhibitor binimetinib reduced the risk of progression or death by 46% compared with vemurafenib for patients with <em>BRAF</em>-mutant unresectable melanoma.

Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab have demonstrated that the combination was well-tolerated with no dose-limiting toxicities in early-stage melanoma.

Cabozantinib demonstrated clinical activity in patients with advanced carcinoid and pancreatic neuroendocrine tumors, according to the results of a single-arm phase II study.&nbsp;

In an analysis of 2 randomized trials,patients with advanced gastric or gastroesophageal juncture cancer derived a survival benefit from treatment with the monoclonal antibody ramucirumab, regardless of their age.<br /> &nbsp;

Supporting the concept of post-progression survival and the influence of different patterns of progression, a new analysis showed patients with advanced HCC had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression.

Continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.

The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy.

Roy Herbst, MD, PhD, discusses the next steps with pembrolizumab in non-small cell lung cancer following its FDA approval, including combination regimens. &nbsp;

Chi Van Dang, MD, PhD, has been appointed scientific director of the Ludwig Institute for Cancer Research.

Genetic counselor Krista Qualmann, MS, CGC,&nbsp;discusses the syndromes she is identifying in patients in her clinic, as well as how they could impact brain tumor treatment.

The use of tumor treating fields as a treatment for patients with brain tumors has, thus far, largely been focused on in glioblastoma, but an upcoming trial aims to expand the use of the device to the grade III patient population, says Daniel O&rsquo;Connell, MD.

Martin J. Edelman, MD, has joined Fox Chase Cancer Center as chair of the Department of Hematology/Oncology and deputy cancer center director for clinical research.